WST · NYSE · STOCK
West Pharmaceutical Services (WST) Stock Analysis
$362.40
52W $223.83 – $386.00
66/100
$25.68B
46.4
1.14
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is WST Bullish or Bearish?
Bullish.
Innellis AI committee rates West Pharmaceutical Services (WST) Buy with a composite score of 66/100
, based on 6 analysts with 83% agreement.
Last updated September 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.05 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.95 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is low leverage (debt-to-equity 0.07) -- balance sheet can absorb a shock. The main limiting factor is p/e of 43.1 is expensive by classic value standards. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- ROE of 18.5% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 43.1 is expensive by classic value standards — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 79 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 17, 2026
Overall Committee Score
66/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 5%
of 192 Healthcare peers
Value Analyst
neutral
49
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 18.5% shows genuine earnings power backing the valuation
− P/E of 43.1 is expensive by classic value standards
Growth Analyst
bullish
77
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 79 is in overbought territory
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.07) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 39 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Investment Thesis Evolution
Committee score moved marginally from 66.0 to 66.0.
Comparing 2026-09-16 to 2026-09-17 (1 day apart).
Technical Analysis
RSI (14)
78.7
Overbought
MACD Histogram
1.862
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$325.81
Resistance
$383.12
Bollinger %B
1.12
Above Upper Band
Price vs Moving Averages
EMA 9
$348.84
Above
EMA 21
$346.95
Above
EMA 50
$343.84
Above
EMA 200
$307.21
Above
Fundamental Analysis
Valuation
5
Growth
89
Profitability
76
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
46.4×
P/B Ratio
8.64×
PEG Ratio
2.71
Dividend Yield
0.24%
52W High
$386.00
52W Low
$223.83
Quality & Growth
ROE
1554.5%
ROA
1156.2%
Gross Margin
3676.5%
Operating Margin
2063.7%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
P/E ratio of 46.4 (rich relative to a 15-40x range); Price-to-book of 8.6x; PEG ratio of 2.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 15.5%; Return on assets of 11.6%; Net margin of 17.0%; Gross margin of 36.8%; Current ratio of 2.82 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow per share is positive (6.17); Most recent quarter beat estimates by 12.8%; 5 consecutive earnings beats; EPS growth accelerating (+4.4% -> +11.3% QoQ); Average YoY EPS growth of 28.8%; Analyst estimates rising over recent quarters
Get the Full WST Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →